BioMarin Pharmaceutical, pioneer in rare disease treatments for phenylketonuria, receives FDA approval of label expansion
October 08, 2020
Cary Harding, M.D., is cited in a BioMarin Pharmaceutical Inc. news release announcing the FDA has approved increasing the maximum allowable dose of Palynziq for adults with Phenylketonuria.